These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 15795559)
1. Nuclear peroxisome proliferator-activated receptors and thiazolidinediones. Grinberg A; Park KW Int Anesthesiol Clin; 2005; 43(2):1-21. PubMed ID: 15795559 [No Abstract] [Full Text] [Related]
2. PPAR Agonists and Metabolic Syndrome: An Established Role? Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003 [TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone and lipid metabolism. Ferrannini E Diabetologia; 2005 Jan; 48(1):6-7. PubMed ID: 15624094 [No Abstract] [Full Text] [Related]
6. Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies? Boulanger H; Mansouri R; Gautier JF; Glotz D Nephrol Dial Transplant; 2006 Oct; 21(10):2696-702. PubMed ID: 16880183 [No Abstract] [Full Text] [Related]
7. [Lessons Learned after 25 Years of Studies on the Physiological Roles of the Peroxisome Proliferator-activated Receptor]. Motojima K Yakugaku Zasshi; 2015; 135(10):1083-9. PubMed ID: 26423862 [TBL] [Abstract][Full Text] [Related]
8. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Friedland SN; Leong A; Filion KB; Genest J; Lega IC; Mottillo S; Poirier P; Reoch J; Eisenberg MJ Am J Med; 2012 Feb; 125(2):126-33. PubMed ID: 22269613 [TBL] [Abstract][Full Text] [Related]
9. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Kolatkar NS Am J Med; 2013 Mar; 126(3):e11. PubMed ID: 23410570 [No Abstract] [Full Text] [Related]
16. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. Qi Z; Xue J; Zhang Y; Wang H; Xie M Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands. Warshawsky AM; Alt CA; Brozinick JT; Harkness AR; Hawkins ED; Henry JR; Matthews DP; Miller AR; Misener EA; Montrose-Rafizadeh C; Rhodes GA; Shen Q; Vance JA; Udodong UE; Wang M; Zhang TY; Zink RW Bioorg Med Chem Lett; 2006 Dec; 16(24):6328-33. PubMed ID: 17005394 [TBL] [Abstract][Full Text] [Related]
18. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Eldor R; DeFronzo RA; Abdul-Ghani M Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S162-74. PubMed ID: 23882042 [No Abstract] [Full Text] [Related]
19. Safety issues and prospects for future generations of PPAR modulators. Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730 [TBL] [Abstract][Full Text] [Related]
20. [Molecular pharmacology and medicinal chemistry of fibrate]. Steinhilber D; Schubert-Zsilavecz M Pharm Unserer Zeit; 2007; 36(2):108-12. PubMed ID: 17424995 [No Abstract] [Full Text] [Related] [Next] [New Search]